Chiesi USA Stock Price, News & Analysis (NASDAQ:CRTX)

Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

About Chiesi USA (NASDAQ:CRTX)

Cornerstone Therapeutics Inc. is a specialty pharmaceutical company focused on commercializing products for the hospital, respiratory and related specialty markets. The Company's promoted products include CUROSURF, ZYFLO CR, FACTIVE and SPECTRACEF. On December 30, 2011, the Company acquired Cardiokine, Inc., a specialty pharmaceutical company, focused on developing hospital products for cardiovascular indications. In March 2012, it acquired the North American product rights for FACTIVE (Gemifloxacin Mesylate) tablets. In June 2012, the Company acquired EKR Therapeutics, Inc. In February 2014, Chiesi Farmaceutici S.p.A acquired Cornerstone Therapeutics Inc.

Receive CRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Generic Pharmaceuticals


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding SharesN/A

Chiesi USA (NASDAQ:CRTX) Frequently Asked Questions

What is Chiesi USA's stock symbol?

Chiesi USA trades on the NASDAQ under the ticker symbol "CRTX."

Who are some of Chiesi USA's key competitors?

Who are Chiesi USA's key executives?

Chiesi USA's management team includes the folowing people:

  • Kenneth R. McBean, President (Age 48)
  • Craig Alexander Collard, Chief Executive Officer
  • Alastair S. McEwan, Chief Financial Officer, Treasurer, Secretary (Age 62)
  • Andreas Maetzel, Vice President - Clinical and Regulatory (Age 50)
  • Alan T. Roberts, Vice President - Scientific Affairs (Age 47)
  • Joshua B. Franklin, Vice President - Strategy and Business Development (Age 44)
  • Ugo Di Francesco, Director

How do I buy Chiesi USA stock?

Shares of Chiesi USA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Chiesi USA?

Chiesi USA's mailing address is 1255 Crescent Grn Ste 250, CARY, NC 27518-8128, United States. The specialty pharmaceutical company can be reached via phone at +1-919-6786611.

MarketBeat Community Rating for Chiesi USA (CRTX)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  34 (Vote Outperform)
Underperform Votes:  49 (Vote Underperform)
Total Votes:  83
MarketBeat's community ratings are surveys of what our community members think about Chiesi USA and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Chiesi USA (NASDAQ:CRTX) Analyst Ratings History

No equities research coverage for this company has been tracked by MarketBeat


Chiesi USA (NASDAQ:CRTX) Earnings History and Estimates Chart

Earnings by Quarter for Chiesi USA (NASDAQ:CRTX)

Chiesi USA (NASDAQ CRTX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2013Q3 2013$0.45$53.70 millionViewN/AView Earnings Details
8/6/2013Q2 2013$0.12$0.19$35.79 million$40.40 millionViewN/AView Earnings Details
5/9/2013Q1 2013$0.22$35.40 million$37.98 millionViewN/AView Earnings Details
3/14/2013Q4 2012$0.30$0.20ViewN/AView Earnings Details
11/8/2012Q312$0.32$0.19$32.00 million$37.50 millionViewN/AView Earnings Details
8/9/2012Q2 2012($0.04)$0.08ViewN/AView Earnings Details
5/15/2012Q1 2012$0.08($0.08)ViewN/AView Earnings Details
3/8/2012Q4 2011($0.02)($0.06)ViewN/AView Earnings Details
11/3/2011$0.02$0.13ViewN/AView Earnings Details
8/4/2011$0.06$0.11ViewN/AView Earnings Details
5/12/2011$0.15$0.17ViewN/AView Earnings Details
3/3/2011$0.12$0.20ViewN/AView Earnings Details
11/4/2010Q3 2010$0.03$0.14ViewN/AView Earnings Details
8/5/2010Q2 2010$0.11$0.08ViewN/AView Earnings Details
5/4/2010Q1 2010$0.15$0.27ViewN/AView Earnings Details
3/4/2010Q4 2009($0.04)$0.19ViewN/AView Earnings Details
11/4/2009Q3 2009$0.01$0.06ViewN/AView Earnings Details
8/11/2009Q2 2009$0.33$0.13ViewN/AView Earnings Details
5/7/2009Q1 2009$0.17$0.48ViewN/AView Earnings Details
3/26/2009Q4 2008$0.13$1.03ViewN/AView Earnings Details
10/20/2008Q3 2008($1.00)($0.46)ViewN/AView Earnings Details
8/11/2008Q2 2008($2.50)($1.34)ViewN/AView Earnings Details
5/8/2008Q1 2008($2.30)($2.52)ViewN/AView Earnings Details
3/27/2008Q4 2007($2.30)($2.71)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Chiesi USA (NASDAQ:CRTX) Earnings Estimates

No earnings estimates for this company have been tracked by


Dividend History for Chiesi USA (NASDAQ:CRTX)

No dividend announcements for this company have been tracked by

Insider Trades

Chiesi USA (NASDAQ CRTX) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Chiesi USA (NASDAQ:CRTX)

Chiesi USA (NASDAQ CRTX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/3/2014Farmaceutici Spa ChiesiMajor ShareholderBuy11,542,313$9.50$109,651,973.50View SEC Filing  
(Data available from 1/1/2013 forward)


Chiesi USA (NASDAQ CRTX) News Headlines

No headlines for this company have been tracked by

SEC Filings

Chiesi USA (NASDAQ:CRTX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Chiesi USA (NASDAQ:CRTX) Income Statement, Balance Sheet and Cash Flow Statement


Chiesi USA (NASDAQ CRTX) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.